New Jersey Pharmaceutical Company Settles Pesticides Violations

The U.S. Environmental Protection Agency (EPA) announced today that it reached an agreement with Pharmaceutical Innovations of Newark, New Jersey resolving alleged violations of the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA). The EPA had alleged that Pharmaceutical Innovations sold and distributed the unregistered and misbranded antimicrobial pesticides “PI Spray” and “PI Spray 2.”

The unregistered and misbranded pesticides were used to clean ultrasound and mammography equipment and other surfaces in health care facilities. As a result of the settlement, Pharmaceutical Innovations stopped producing and selling their unregistered and misbranded products called “PI Spray” and “PI Spray 2” and did a voluntary recall of both products.

“These products were marketed to health care facilities and their patients, which of course relied on the claims that they kill microorganisms, but in this case those claims were not properly substantiated through the EPA registration process,” said Pete Lopez, EPA Regional Administrator. “When the EPA registers products, EPA requires that companies demonstrate that products do what they claim and that they don’t present unacceptable risk if used properly.”

According to the EPA, the product labels, product inserts, and promotional material for both products:

  • made unsubstantiated claims to control bacteria and kill viruses;
  • made unsubstantiated claims as to the efficacy and safety of the product; and
  • did not list the inert ingredients or bear the name and percentage by weight of each active and inert ingredient.

In the settlement, Pharmaceutical Innovations agreed to pay a civil penalty of $250,000 and certified that it has come into compliance with FIFRA.  

The sale and distribution of unregistered and misbranded antimicrobial pesticides pose a danger to people’s health. Without the company’s submission of efficacy and safety data and product labels to EPA for review and approval, as required by law, health care facilities and their patients may use the product inappropriately and are deprived of important health and safety information.

No Comments Yet

Leave a Reply

Your email address will not be published.

©2020. Global Health News Wire. Use Our Intel. All Rights Reserved. Washington, D.C.